Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
SAN FRANCISCO, Jan. 24, 2017 -- Hagens Berman Sobol Shapiro LLP alerts investors in Novo Nordisk A/S (NYSE:NVO) to the expanded class period and reminds them of the March 13, 2017 Lead Plaintiff deadline.
If you purchased or otherwise acquired NVO between February 5, 2015 and October 27, 2016 and suffered over $100,000 in losses contact Hagens Berman Sobol Shapiro LLP. For more information visit:
https://www.hbsslaw.com/cases/NVO
or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing [email protected].
After repeatedly assuring investors of sales and profit growth, NVO announced its second consecutive quarter of disappointing earnings and slashed long-term profit-growth forecasts by 50% on October 28, 2016. In addition, NVO revealed it was being investigated by the U.S. Attorney’s Office for potentially improper arrangements with pharmacy benefits managers who purchase NVO’s insulin products. This news drove the price of the Company’s ADRs down approximately 13%.
“We’re focused on NVO’s insulin, and other, pricing-related matters and Defendants’ growth-related statements,” said Hagens Berman partner Reed Kathrein.
Whistleblowers: Persons with non-public information regarding NVO should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email [email protected].
About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with offices in 10 cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the Firm and its successes can be found at www.hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Contact: Reed Kathrein, 510-725-3000
